Our study represents an unmet medical need and focusses on the repurposing of dutasteride to improve therapy response and clinical outcome for patients with R/M SDC having limited other treatment options available, especially when tumours are HER2 negative. The gene discussed is ERBB2; the disease is neoplasm.